Dudediligence.

REGENXBIO Inc

RGNXNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$1,193,480

4 notices · 104,058 sh

Oct 2025 to Oct 2026

Reported ·

$484,373

3 sales · 0 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

All 3 reported sales carry the 10b5-1 box. Together they are 0.06% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-07-01: Stephen J. Pakola, Form 1442026-05-11: STEPHEN PAKOLA, Form 1442026-03-10: STEPHEN J PAKOLA, Form 1442025-10-09: CURRAN M SIMPSON, Form 1442025-10-09: Simpson Curran, sold2026-03-10: PAKOLA STEVE, sold2026-05-11: PAKOLA STEVE, sold
under a ▼ salesize is dollars

Form 144 notices, newest first

2026-07-01Stephen J. Pakola, Chief Medical Officer$517,608
43,206 shplan 2025-11-12Form 4s on file end Jun 23144 ↗
2026-05-11STEPHEN PAKOLA, Chief Medical Officer$368,374
34,917 shplan 2025-11-12144 ↗
Form 4, 2026-05-13: sold 15,309 at $11.02 Form 4 ↗
2026-03-10STEPHEN J PAKOLA, Chief Medical Officer$53,187
5,124 shplan 2025-11-12144 ↗
Form 4, 2026-03-12: sold 5,124 at $10.35 Form 4 ↗
2025-10-09CURRAN M SIMPSON, Chief Executive Officer$254,310
20,811 shplan 2025-03-28144 ↗
Form 4, 2025-10-10: sold 20,811 at $12.62 Form 4 ↗